Sung Baek Jeong

Title: Innovations by Sung Baek Jeong in Cancer Treatment

Introduction

Sung Baek Jeong is a notable inventor based in Seoul, South Korea. He has made significant contributions to the field of pharmaceuticals, particularly in the treatment of cancer. With a total of 2 patents, his work focuses on innovative compositions that target specific cancer types.

Latest Patents

Sung Baek Jeong's latest patents include a pharmaceutical composition comprising 2,4,6-trihydroxyacetophenone (THA) as an active ingredient for treating breast cancer. This composition is designed to inhibit the activity of polo-like kinase 1 (PlK1), which plays a crucial role in cancer progression. Another significant patent involves a pharmaceutical composition for the treatment of prostate cancer, also utilizing THA. This invention aims to effectively inhibit the growth of prostate cancer by regulating the activity of PLK1, showcasing its potential for future applications in cancer prevention and treatment.

Career Highlights

Sung Baek Jeong is associated with Korea United Pharm, Inc., where he continues to develop innovative solutions in the pharmaceutical industry. His research and inventions are paving the way for new therapeutic options for patients suffering from cancer.

Collaborations

He collaborates with esteemed colleagues such as Keon Wook Kang and Kwang-Seok Oh, contributing to a dynamic research environment that fosters innovation.

Conclusion

Sung Baek Jeong's work exemplifies the impact of innovative thinking in the pharmaceutical field, particularly in cancer treatment. His contributions are expected to lead to significant advancements in therapeutic strategies for breast and prostate cancer.